+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
All Ages
All Genders
ID01555892

Study of New EBV-Specific T Cell Therapy for Patients With EBV-Positive Hodgkins or Non-Hodgkins Lymphoma and Related Diseases

Led by Baylor College of Medicine · Updated on 2026-03-02

136

Participants Needed

3

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the use of specially trained immune cells called GRALE T cells for patients with certain types of lymph gland diseases, including Hodgkins Disease, Non-Hodgkins Lymphoma, TNK-lymphoproliferative disease, or severe chronic active Epstein Barr Virus CAEBV. These diseases either have returned, are at risk of returning, or have not responded to previous treatments. The study focuses on patients whose tumors show the Epstein Barr virus, which can hide from the immune system and may contribute to these cancers. Researchers want to see if GRALE T cells can survive in the blood and impact the tumor. Participants or their donors will provide blood to grow EBV-specific GRALE T cells in the lab. Some patients may receive chemotherapy drugs cyclophosphamide and fludarabine to prepare their blood for the T cells. The GRALE T cells will be thawed and infused into patients over a few minutes, with two doses given two weeks apart. If there is a partial response or stable disease after these doses, patients may receive up to six additional infusions. Treatments are given at specialized centers, and patients may or may not receive chemotherapy to help the T cells grow. Throughout the study, participants will have scans and blood tests to assess tumor size and immune response. After infusions, patients will be followed regularlyevery three months for a year, then yearly for up to five yearsto monitor safety and effectiveness. The main outcome is to determine the highest safe dose of these T cells and observe side effects. Researchers will also study how well the T cells survive and their anti-viral and anti-tumor effects over one year.

CONDITIONS

Brief Title

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

Research Team

H

Helen E Heslop, MD

V

Vicky Torrano

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here